United States (US) Nonalcoholic Steatohepatitis Therapeutics Market (2025-2031) | Outlook, Industry, Value, Companies, Forecast, Size & Revenue, Segmentation, Trends, Analysis, Share, Growth, Competitive Landscape

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market - Industry Life Cycle

3.4 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market - Porter's Five Forces

3.5 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume Share, By Drug Type, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of nonalcoholic steatohepatitis (NASH) in the US population

4.2.2 Growing awareness about the disease leading to early diagnosis and treatment

4.2.3 Technological advancements in drug development for NASH therapeutics

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for drug approval in the NASH market

4.3.2 High cost associated with NASH therapeutics impacting affordability and access

4.3.3 Limited understanding of the disease mechanism leading to challenges in developing effective treatments

6.1 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market, By Drug Type

6.1.1 Overview and Analysis

6.1.2 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Drug Type, 2021- 2031F

6.1.3 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Obeticholic Acid (OCA), 2021- 2031F

6.1.4 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Aramchol (Arachidyl Amido Cholanoic Acid), 2021- 2031F

6.1.5 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Saroglitazar, 2021- 2031F

6.1.6 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Elafibranor, 2021- 2031F

7.1 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Export to Major Countries

7.2 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Imports from Major Countries

8.1 Patient adherence rate to NASH therapeutics

8.2 Rate of adoption of novel treatment approaches in NASH management

8.3 Number of clinical trials focusing on NASH therapeutics

8.4 Improvement in NASH biomarkers through research advancements

8.5 Patient-reported outcomes related to quality of life and symptom management in NASH

9.1 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Opportunity Assessment, By Drug Type, 2021 & 2031F

10.1 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Revenue Share, By Companies, 2024

10.2 United States (US) Nonalcoholic Steatohepatitis Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters